Abstract:
The severe neurological tumor known as glioblastoma (GBM), also referred to as a grade IV astrocytoma, is rapidly progressive and debilitating. Supratotal resection (SpTR) is an emerging concept within glioma surgery, which aims to achieve a more extensive resection of the tumor than is possible with conventional techniques. We performed a language-independent search of PubMed, Scopus, and Cochrane central to identify all available literature up to August 2022 of patients undergoing SpTR assessing survival outcomes in comparison to other surgical modalities. After screening for exclusion, a total of 13 studies, all retrospective in design, were identified and included in our meta-analysis. SpTR was associated with significantly increased overall survival (HR=0.77, [0.71-0.84]; p<0.01, I2=96%) and progression-free survival (HR=0.2, [0.07-0.56]; p=0.002, I2=88%). In conclusion, we found that SpTR is associated with greater overall and progression-free survival when compared to other glioblastoma surgeries like GTR or SubTR. The present study suggests that SpTR can be a useful strategy for improving outcomes in glioma surgery, but it should be balanced against the potential risks and individual patient factors. Further research is required to determine the benefits and downsides of this treatment and to specify the ideal level of resection for the different subtypes of glioma.
Page(s):
DOI:
DOI not available
Published:
Journal: Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 , Volume: 0, Issue: 0, Year: 2023